Another Step Closer to Eye Drops for Wet Macular Degeneration

By Dan Roberts - MD Support

Scientists at the University of Birmingham are one step closer to developing an eye drop that could revolutionize treatment for wet age-related macular degeneration. The condition is currently treated by injections of anti-VEGF drugs into the eye.

Eye drops have already been tested successfully in rats. This latest study, published in Investigative Ophthalmology & Visual Science (IOVS), demonstrates that eye drops can deliver a therapeutically effective amount of drugs to the retina of larger mammalian eyes like rabbits and pigs.

Pending patents for the eye drops are now owned by U.S. based company Macregen Inc. A team of U.K. researchers at the University of Birmingham Institute of Microbiology and Infection is working with the company to develop a novel range of therapies for wet AMD and other eye diseases.

The combined team is expediting proof of concept studies. Upon completion, clinical trials could begin as early as the Spring 2019.

A video interview with the researcher available here: https://macularnews.org/2018/07/19/arvo-2018-dr-felicity-de-cogan/
A Letter from Liz

Liz Traurnicht - Pres
MD Foundation

Don’t be Shy to Ask Your Primary Care Physician (PCP) ...

A report from the National Poll on Healthy Aging reveals that more than half of older patients surveyed said their primary care providers have not asked them about their vision. Considering the number of ailments that can affect the aging population, vision is 3rd and unfortunately often overlooked.

This is concerning since the incidence of age-related macular degeneration (AMD) will likely increase as the number of senior adults grows. There is not yet a cure for the “dry” form of the disease, but the “wet” form (wherein blood vessels leak into the retinal layers) can be treated if caught early. The survey solicited responses from 2,013 participants from ages 50 to 80 years with the following results: • 58% said their primary health care provider did not ask about vision. • 27% said they had been diagnosed with cataracts, diabetic eye disease, glaucoma or macular degeneration. • 17% said they had their vision checked using an eye chart at a primary care visit. • 91% had an eye exam within 2 years of a PCP asking about their vision.

The researchers wrote that “Findings from this poll underscore the important role that primary care providers play in promoting eye health. People with diabetes, a history of eye disease, or lower household incomes were more likely to have had a conversation about vision with their primary care provider, suggesting that primary care providers may be more likely to discuss eye health with those known to be at high risk for eye conditions”. AMD, however, does not always show symptoms until it has progressed significantly. For that reason, every senior adult should request that at least a cursory eye exam be performed at each annual physical.

Dan Roberts - MD Support
Go Go Grandparent (gogograndparent.com) was started 3 years ago to offer ride-sharing opportunities to those without smart phones and necessary apps. It is available wherever Uber or Lyft is operating.

This means that instead of contacting Uber or Lyft yourself, you may call Go Go Grandparent with a regular phone and they make all the arrangements for you. This includes, arrival time, cost and notifying the driver of any special needs or disabilities.

The company says that it only selects drivers with a 4.9 or greater rating with Uber or Lyft. The cost of Go Go Grandparent is 27 cents per minute of transportation time. This is added to the basic fare charged by Uber or Lyft, which depends on location, time of day, availability and other factors. On several recent rides using Go Go Grandparent with Uber, the added cost was slightly more than 20% of the total cost. Tipping is by cash at the discretion of the client.

You may join this company with no contract or commitment by calling 855-464-6872. A credit card is required.

Authors: Joe Fontenot MD, CLV and Peyton Clarkson
Community Services for Vision Rehabilitation
600 Bel Air Blvd, Suite 110 Mobile, Alabama
The inability to recognize faces is one of the most common complaints of people with age-related macular degeneration and is a frequent cause of embarrassments and concern in social activities.

If you have AMD, you will have blind spots in the center of your vision (central scotomas) and decreased contrast sensitivity. The blind spots will occupy part of a person’s face and the impaired contrast sensitivity prevents you from seeing shades of texture and color. Since the blind spots are funnel-shaped, being smaller at close distance and greater at further distance, you will have less difficulty recognizing people up close. You will begin to recognize people by their voice, the way they walk and dress, their size, height and other characteristics. The problem with this sort of recognition is that it is not as quick or exact as normal face recognition.

Face recognition is an important part of everyday life. We recognize people, hail them and begin a social dialog. The ability to do this is important in order to respond appropriately or know what to say. Some people may be offended if we do not recognize them.

What can be done? At a distance, any telescopic magnifier will help. It has been shown that bioptic glasses (glasses with a small telescope mounted in the upper part of the glasses) does help identify people. The new head-mounted mounted electronic magnifiers (Iris Vision, Patriot, Nu Eyes, etc.) do help. However, these are difficult to use in ordinary circumstances such as walking and would not be comfortable in some social events.
Simple Tips to Recognize Faces

* Speak up. Sometimes simply saying “Hello” or “Good day” will elicit a response that identifies the person or you will recognize their voice.

* If the situation is appropriate, get closer. This makes your blind spot smaller, covering less of their face.

* Engaging in small talk will give you clues as to identity.

* Moving to the side where the person’s face is least in shadow may help and you may recognize them better from a different angle. Also, try positioning yourself so the light is behind you and on the face of the person you are trying to identify.

* Knowledge of your scotoma position and your “preferred retinal focus” will help in directing your gaze so that more of the person’s face will be visible.

* As always with vision loss, plan ahead. If you are going to meet a small group of people, find out ahead of time who they will be and this will help with recognition.

* If all else fails, simply say “I’m sorry, I have macular degeneration and I have trouble identifying people. What is your name?”

* If you are with a close friend or family member, you can quietly ask them to identify people as they approach.

* A white-tipped cane will make it obvious why you do not recognize people.

* There are also lapel pins saying “I have Low Vision” and you can simply call attention to the pin.

Remember that a minor degree of embarrassment is better than staying at home. Get out there! Say “Hello” to everyone.

by Joseph L. Fontenot MD, CLVT
Medical Dir: Community Services for Vision Rehabilitation
600 Bel Air Blvd, Suite 110 Mobile, Alabama
**FTC Stops Deceptive Claims About Stem Cell Therapy**

A California-based physician and the two companies he controls have settled charges of deceptively advertising that “amniotic stem cell therapy” can treat serious diseases, including Parkinson’s disease, autism, macular degeneration, cerebral palsy, multiple sclerosis, and heart attacks.

The defendants even claimed that the therapy could restore the vision of blind patients, citing the case of a “101 year old Lady once blind for 7 years” who, thanks to stem cell therapy, could see again. According to the Federal Trade Commission report, Dr. Bryn Jarald Henderson, D.O. and the two companies he owns and operates (Regenerative Medical Group and Telehealth Medical Group), earned at least $3.31 million offering stem cell therapy between 2014 and 2017.

Initial stem cell therapy injections ranged from $9,500 to $15,000, with patients encouraged to undergo multiple treatments. Follow-up “booster” treatments cost between $5,000 and $8,000 each. The settlement prohibits the defendants from making these and other health claims in the future unless the claims are true and supported by competent and reliable scientific evidence. The settlement also imposes a partially suspended $3.31 million judgment and requires the defendants to notify current and former patients about the order within 30 days.

This action should serve as a warning to other companies who are making unsubstantiated claims about stem cell “cures”. At this time, no stem cell treatments for retinal diseases have been approved for clinical use by the US Food and Drug Administration (FDA). Anyone considering participation in a clinical trial should ask if the FDA has reviewed the treatment. An honest health care provider would be able to confirm this information by providing a New Drug Application (NDA) number and the chance to review the FDA communication approving its experimental use. Ask for this information before getting treatment—even if the stem cells are your own.

by Dan Roberts - ILVSG Newsletter Vol 13, Issue 11

---

**Definitions**

**Ophthalmologist**
a practitioner in the medical science of surgery and care of the eye and its related structures. An M.D. degree is required.

**Retina specialist**
a medical doctor trained as an ophthalmologist, who has received additional training in diseases and surgery of the retina and vitreous.

**Optometrist**
a degree (O.D.), independent, primary health care provider skilled in the co-management of eye health and vision care, including examination, diagnosis, treatment, management of diseases/disorders, prescription of eyeglasses/contact lenses, and provision of low vision aids and therapy.

**Optician**
a person who designs or manufactures ophthalmic appliances or optical instruments (“ophthalmic optician”) or deals in prescriptions (“dispensing optician”).
Exclusive Online Videos Featuring World’s Leading Eye Researchers

The Macular Degeneration Foundation interviews the world’s foremost scientists, medical practitioners and inventors. Visit MacularNews.org for the latest news and register to receive an email notice when new videos are first posted.

Donations

The Macular Degeneration Foundation, Inc. is a tax-exempt, non-profit organization.

Please visit our website at eyesight.org to make a tax deductible donation.

Checks may be mailed to:

Macular Degeneration Foundation, Inc.,
P.O. Box 531313,
Henderson, NV 89053

Call: 888-633-3937 (USA)
Call: 702-450-2908 (Intl)
Email: liz@eyesight.org

Disclaimer - Articles in the Magnifier are for information only and are not an endorsement by the Macular Degeneration Foundation editorial staff.

Page 7
Genentech’s Faricimab for Wet AMD May Extend Time Between Injections

Genentech has announced positive results from the Phase II STAIRWAY study which explored the extended durability of faricimab (RG7716) in the treatment of wet age-related macular degeneration (AMD).

According to Sandra Horning, M.D., chief medical officer and head of Global Product Development, “The STAIRWAY data show the potential of faricimab to allow fewer injections while achieving and sustaining the same visual gains seen with a current standard of care.”

Based on these results, a global Phase III program for faricimab is anticipated to start in 2019.